Market News & Trends
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial for the Treatment of Spinal & Bulbar Muscular Atrophy
Avenue Therapeutics, Inc. recently announced all patients have been enrolled in the Phase 1b/2a clinical trial of AJ201 for the treatment of spinal and bulbar…
Silo Pharma & Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia
Silo Pharma, Inc. recently announced an update on its dosage and time-release ketamine-loaded implant, designated as SP-26, which is being developed as a potential at-home…
Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application
Zevra Therapeutics, Inc. recently announced it resubmitted its New Drug Application (NDA) for arimoclomol, an investigational therapeutic candidate for the treatment of Niemann-Pick disease type…
Sever Pharma Solutions Secures DEA License for Controlled Substances Handling in Putnam, CT
Sever Pharma Solutions recently announced the successful attainment of the Drug Enforcement Administration (DEA) license for its site in Putnam, CT. This license, effective as….
4DMT Receives FDA Regenerative Medicine Advanced Therapy Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
4D Molecular Therapeutics recently announced the US FDA has granted the RMAT designation for the investigational genetic medicine candidate 4D-150 for intravitreal treatment of wet…
Thermo Fisher Scientific’s PPD Clinical Research Business Selected by BARDA to Support Phase 2 Platform Clinical Trial to Treat ARDS
The PPD clinical research business of Thermo Fisher Scientific Inc., the world leader in serving science, has been selected by the Biomedical Advanced Research and…
BriaCell Reports Unprecedented Preliminary Survival & Clinical Benefit in Antibody-Drug Conjugate Refractory Patient Subset
BriaCell Therapeutics Corp. recently reported unprecedented preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell’s Bria-IMT…
Abzena Partners With FDA on MAPPs Assay Publication
Abzena has recently co-authored a publication with the US FDA demonstrating the potential of the MHC Associated Peptide Proteomics (MAPPs) assay as an important method to interrogate immunogenicity risk….
ImmunoScape & MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification & Therapeutic Development
ImmunoScape and MiNK Therapeutics, Inc. recently announced a collaboration agreement to discover and develop next-generation TCR therapies against novel targets in solid tumors. The combined efforts…
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress & Key Milestones Accomplished
Lipella Pharmaceuticals Inc. recently celebrated its first anniversary as a publicly traded entity. Based in Pittsburgh, PA, the company has made substantial strides over the past year, achieving critical milestones….
Enlivex Announces Completion of Enrollment of its Phase 2 Trial Evaluating Allocetra in Patients With Sepsis
Enlivex Therapeutics Ltd. recently announced it has completed enrollment of all 120 patients in its Phase 2 trial of Allocetra in patients with sepsis. The…
Kronos Bio Announces Pipeline Update & p300 KAT Inhibitor Development Candidate
Kronos Bio, Inc. recently announced an update on its pipeline. After a review of data from the Phase 1b portion of its Phase 1b/2 trial…
Biora Therapeutics Announces New Patent for its NaviCap Targeted Oral Delivery Platform
Biora Therapeutics, Inc. recently announced it received an Issue Notification from the US Patent and Trademark Office for a patent related to the treatment of…
Nectin Therapeutics Adds Combination Therapy Arm & Expands Sites in Phase 1 Clinical Trial of Its First-in-Class Anti-PVR Immune-Oncology Agent
Nectin Therapeutics Ltd. recently announced it has progressed its Phase 1 clinical trial of NTX1088 to include a combination therapy arm with the immune-oncology drug…
Ethris Initiates First-in-Human Dosing in Phase 1 Study for the Treatment of Virus-Induced Asthma
Ethris GmbH recently announced the dosing of the first healthy participant in its first-in-human study of lead candidate ETH47, which was developed using Ethris’ Stabilized…
Successful Transfer of NDA Acknowledged by FDA From Former Zosano Pharma to Emergex for Investigational Microneedle-Based Drug Delivery Patch
Emergex Vaccines Holding Limited recently announced the company has transferred ownership, as of May 2023, of the existing US FDA New Drug Application (NDA) of the investigational MAP originally intended….
Revive Therapeutics Collaborates With Attwill Medical Solutions for the Clinical & Commercial Development of a Novel Lyophilized Formulation of Bucillamine
Revive Therapeutics Ltd. recently announced it has signed a collaboration agreement with Attwill Medical Solutions LP (AMS) for the clinical and commercial development of the…
Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
Unicycive Therapeutics, Inc. recently announced the enrollment of the first patient in its open-label, single-arm, multicenter, multidose pivotal clinical trial with Oxylanthanum Carbonate (OLC). OLC…
POINT Biopharma & Lantheus Announce Positive Topline Results From Pivotal SPLASH Trial in Metastatic Castration-Resistant Prostate Cancer
POINT Biopharma Global Inc. and Lantheus Holdings, Inc. recently announced statistically significant topline results from the pivotal….
Global Confidence in Drug Delivery Innovation Remains at Record Highs According to Pharmapack
The annual Pharmapack Drug Delivery Innovation Index is released ahead of Europe’s premier drug delivery and packaging event, Pharmapack Europe 2024 (January 24-25) – held at the Paris Expo, Porte de Versailles (Hall 7.2). The results showed….
